Background: 2013 AHA/ACC guidelines on the treatment of cholesterol advised to tailor high-intensity statin after ACS, while previous ATP-III recommended titration of statin to reach low-density lipoprotein cholesterol (LDL-C) targets. We simulated the impact of this change of paradigm on the achievement of recommended targets. Methods: Among a prospective cohort study of consecutive patients hospitalized for ACS from 2009 to 2012 at four Swiss university hospitals, we analyzed 1602 patients who survived one year after recruitment. Targets based on the previous guidelines approach was defined as (1) achievement of LDL-C target < 1.8 mmol/l, (2) reduction of LDL-C 50% or (3) intensification of statin in patients who did not reach LDL-C targets. Targets based on the 2013 AHA/ACC guidelines approach was defined as the maximization of statin therapy at high-intensity in patients aged 75 years and moderate-or highintensity statin in patients >75 years. Results: 1578 (99%) patients were prescribed statin at discharge, with 1120 (70%) at high-intensity. 1507 patients (94%) reported taking statin at one year, with 909 (57%) at high-intensity. Among 482 patients discharged with sub-maximal statin, intensification of statin was only observed in 109 patients (23%). 773 (47%) patients reached the previous LDL-C targets, while 1014 (63%) reached the 2013 AHA/ACC guidelines targetsone year after ACS (p value < 0.001). Conclusion: The application of the new 2013 AHA/ACC guidelines criteria would substantially increase the proportion of patients achieving recommended lipid targets one year after ACS. Clinical trial number, NCT01075868.
Introduction
Statin therapy is strongly recommended in the long-term management of patients with acute coronary syndromes (ACS)
[1e5]. The Adult Treatment Panel (ATP III) recommended reaching a low-density lipoprotein cholesterol (LDL-C) target < 1.8 mmol/l (70 mg/dL) in very high-risk patients, such as patients with ACS [6, 7] . The paradigm of targeting statin dose for a specific LDL-C goal means that an adequate dose of statin should be prescribed or adapted to reach recommended LDL-C [8] . Nevertheless, previous observational studies have shown that poorly controlled LDL-C levels after ACS are common and statin intensification sub-optimal [9e11].
The 2013 AHA/ACC guidelines on the treatment of blood cholesterol abandoned the strategy of using LDL-C targets given the lack of evidence from randomized controlled trials [12] . Patients with ACS are classified as very high-risk patients and physicians have to initiate high-intensity statin in those age 75 years old and moderate-or high-intensity statin in those > 75 years old if no documented contraindications [12] . This new recommended approach represents a change in paradigm regarding statin therapy in secondary prevention, with unknown clinical consequences.
Therapy modification in response to poorly controlled dyslipidemia and achievement of recommended targets have been described as a measure of quality of care [13, 14] . However, little is known regarding the simulated expected impact of applying new 2013 AHA/ACC guidelines criteria compared to previous ATP-III criteria on the achievement of recommended lipid targets. In this study, we described in the same cohort population the achievement of lipid targets according to both guidelines, as well as the associated clinical factors with both approach.
Methods

Study population
We analyzed data from September 2009 to December 2012 of patients included in the SPUM-ACS cohort (NCT01075868). Patients hospitalized with a main diagnosis of ACS at four Swiss academic centers (University of Bern, Geneva, Lausanne and Zürich) were screened and written consent obtained [15] . Inclusion criteria were age older than 18 years with clinical features of ischemia (e.g. chest pain, breathlessness) and at least one of following criteria: (a) persistent ST-segment elevation or depression, T inversion or dynamic ECG changes, new left bundle branch block, (b) evidence of positive troponin or creatine kinase (CK) and (c) evidence of a significant coronary artery disease at the angiography (50% stenosis) [16] . The participants were contacted for a clinical visit at the enrollment site 12 months after hospitalization for ACS. Of 2355 patients discharged from the index hospitalization, the one-year follow-up was performed in 2213 (94%) patients, 52 died, 60 refused follow-up and 30 were lost to follow-up, yielding a final sample of 1602 patients with available data on LDL-C and statin for the main analysis (Supplemental Fig. 1 ).
Statin therapy classification
Based on the 2013 AHA/ACC guidelines on the treatment of cholesterol, we classified statin intensity: (1) high-intensity (atorvastatin 40e80 mg, rosuvastatin 20e40 mg); (2) moderateintensity (atorvastatin 10e20 mg, rosuvastatin 5e10 mg, simvastatin 20e40 mg, pravastatin 40e80 mg, fluvastatin 80 mg) and (3) low-intensity (simvastatin 10 mg, pravastatin 10e20 mg, fluvastatin 20e40 mg) [12] . We defined intensification of statin therapy as a switch to higher potency among patients discharged without highintensity statin (no, low or moderate intensity statin) [11] . If the statin was not prescribed at discharge or discontinued during the year, we collected the documented reasons.
Blood lipid measurements
Baseline LDL-C corresponded to the first available fasting values within the first 24 h of the hospital admission [17e19]. LDL-C was calculated using the Friedewald equation [(total cholesterol-highdensity cholesterol-triglycerides)/2.2], unless trigylcerides were elevated (>4.5 mmol/L) [20] . The one-year lipid profile was collected from venous blood samples after twelve-hour fasting.
Recommended target achievement
At one-year, we defined recommended targets based on new 2013 AHA/ACC guidelines criteria and based on previous ATP-III guidelines criteria [4, 12, 21] . Recommended targets based on previous -ATP-III criteria was defined as the (1) achievement of LDL-C target < 1.8 mmol/l. In patients who did not reach LDL-C targets, (2) we additionally defined as achieved targets the reduction of LDL-C 50% or (3) the intensification of statin therapy (Supplemental Table 1 ) We defined achievement of recommended targets based on the new 2013 AHA/ACC guidelines criteria as the use of highintensity statin therapy in patients aged 75 years and moderate-or high-intensity statin therapy in patients aged > 75 years.
We performed sensitivity analyses to address potential limitations: (1) To take into account the potential modifications of lipid baseline profile after the onset of ACS symptoms, we excluded participants with chest pain duration greater than 24 h at admission [18, 19] . (2) To validate the reported use of statin at one year, we asked in 1472 patients the published self-reported adherence question: « In the past month, how often did you take your medications as the doctor prescribed? ». Possible answers were: « all the time (100%) », « nearly all of the time (75%) », « about half of time (50%) », «less than half the time (<50%) » [22] . In sensitivity analyses, we assessed the achievement of recommended LDL-C targets in patients with complete self-reported adherence to statin (100%) (Supplemental Fig. 1 ) (3) To address potential selection bias related to the missing LDL-C data at the one-year followup, we evaluated the statin intensity in an extended sample of the cohort using data from 2154 patients with available statin intensity (e.g. data collected with phone call) (Supplemental Fig. 1 ).
Statistical analyses
The percentage of patients in various statin intensity categories was summarized at the time of hospital discharge and at one-year follow-up. The percentage of patients reaching the recommended targets at one-year was presented according both guidelines. We used the chi-square test to assess whether proportions were statistically significant. Using logistic regression model adjusted by site, we evaluated the odds ratios (OR) and the 95% confidence intervals (95% CI) of the association between patient factors and the appropriate care targets according to both guidelines. Covariates were selected a priori based on clinical signification: age, gender, working, living, smoking and educational status, history of hypercholesterolemia, of diabetes, of hypertension, of myocardial infarction (MI), prior use of statin, body mass index (BMI), baseline LDL-C levels, final diagnosis of ACS (STEMI vs. NSTEMI/UA) and attendance to cardiac rehabilitation (CR) [11] . As missing LDL-C values at one year could be a source of selection bias, we tested the sensitivity of the reported OR by using inverse probability of censoring weights (IPCW) [23] . The level of significance was established a priori at 2-sided P < 0.05. All patients provided informed consent and each enrolling center obtained institutional review board approval. All analyses were performed using Stata version 12.1 (Stata Corporation, College Station, Texas).
Results
Population characteristics
In our sample of 1602 patients, the mean age of participants was 61.8 ± 12 years, 310 (19%) were female, 225 (14%) had previous history of MI, 977 (61%) had hypercholesterolemia, 897 (56%) presented STEMI (Table 1) . 1121 patients (71%) attended to a CR program after discharge. 1565 (99%) patients had a medical follow-up by physician.
Statin prescription and reasons for non-prescription
1578 (99%) of patients were discharged with statin therapy. Among 24 patients without statin prescription, 7 (29%) patients had documented reasons for non-prescription in the medical records: 3 had statin tolerance or side effects, 2 had another lipid-lowering therapy, 1 had to start in the outpatient, 1 had hepatic enzyme disturbances) and 3 had baseline LDL-C values < 1.8 mmol/l. At one year, 1507 (94%) were treated with statin and 88 (6%) had discontinued statin therapy after discharge. The reasons for discontinuation according to the patients were as follows: the physician stopped the treatment in 37 (42%) patients, 28 (32%) patients stopped due to side effects, 3 (3%) patients could not afford the statin therapy, 10 (11%) patients felt it was unnecessary to continue and in 10 (11%) of cases the reasons were unknown.
Statin therapy intensification
Of the 1602 patients, 1120 were discharged with high-intensity (70%), 444 on moderate-intensity (28%) and 14 (1%) were on lowintensity statin therapy. At one year, the use of high-intensity statin decreased to 57% (909 patients), while the proportion of moderate-intensity statin increased to 35% (560 patients), as well as low-intensity statin to 2% (38 participants) (Fig. 1) . Patients using high-intensity statin at one year were more likely to have wellcontrolled LDL-C targets (64%) compared to those with lowerintensity statin (53%). Of the 472 patients on sub-maximal statin therapy at discharge (no, low or moderate intensity statin), only 109 (23%) had the statin therapy intensified during the year (Table 2) . Most commonly used high-intensity statin at one year were atorvastatin 40 mg (29%) or rosuvastatin 20 mg (23%). (Supplemental Table 2 ) In sensitivity analyses among 2154 participants with complete data on statin use, results were similar: 1487 (69%) patients had maximal statin at discharge and 1205 (56%) at one year.
Recommended targets achievement based on previous and new guidelines
Of the 1602 patients, 552 patients (35%) reached the recommended LDL-C target < 1.8 mmol/l at one year, while 117 patients (7%) reduced LDL-C of 50% and 76 (5%) had an intensification of treatment for those with LDL-C 1.8 mmol/l, yielding to 745 (47%) patients reaching targets of ATP-III guidelines. In secondary analysis using a target LDL-C < 2.6 mmol/l, 1156 patients reached this less stringent target (72%), in addition 13 (1%) had a decrease in LDL-C 50% and 31 (2) had an intensification of statin therapy, yielding to 1200 (75%) patients reaching tailored LDL-C target. At one year, 909 (57%) patients were treated with high-intensity statin and in addition 105 elderly had moderate-intensity, yielding to 1014 (63%) patients reaching targets of 2013 AHA/ACC guidelines » (Fig. 2) . The proportions were highly statistically significant (P value < 0.001). When comparing targets according to both strategies, we observed that 536 (33%) patients had achieved both targets, while 379 (24%) did not achieve any of them, 478 (30%) patients achieved only targets of tailored-statin intensity strategy and 209 (13%) patients achieved only targets of LDL-C targets strategy (Table 3) . Among 1432 patients with data on self-reported adherence, 1223 (85%) patients reported always to take medication as prescribed by the physician. In sensitivity analyses, we found similar results after excluding those without complete selfreported adherence and those with onset of symptoms greater than 24 h. We also performed sensitivity analyses to assess whether LDL-C missing values could be a concern in term of selection bias and found similar rate of patients reaching the 2013 AHA/ACC guidelines (63%).
Factors associated with recommended targets
Using multivariate models, we examined associated factors with achievement of recommended targets based on both guidelines. (Table 4 ) Patients who attended a CR program were more likely to achieve ATP-III criteria (p value 0.01), while those with elevated LDL-C at hospital admission (p value 0.01) and those taking statin prior to ACS (p value 0.001) were less likely. Regarding the new 2013 AHA/AHA guidelines criteria, patients were more likely to reach if they were older (p value < 0.001), obese (p value 0.003), had STEMI (p value 0.006) and had elevated LDL-C at hospital admissions (p value 0.001). In sensitivity analyses, the ORs were unchanged after IPCW (Supplemental Table 3 ).
Discussion
Main findings
In this prospective cohort of patients with ACS, we found that 
Added value of our findings
Few prospective studies assessed statin therapy intensity and modification in patients hospitalized with ACS. The TRIUMPH registry among 4340 patients hospitalized with myocardial infarction (MI) reported a high prescription (90%) of statin at hospitalization, but uncommon (23e26%) intensification and maximization of statin after hospitalization [11] . In the same registry, only one-third of patients met the recommended LDL-C target < 100 mg/dL [9] . The sub-optimal dosage of statin prescription in secondary prevention, as well as the poor achievement of LDL-C targets (less than 40%) was also reported in two other US registries of patients with ACS [1014] . We found also a sub-optimal achievement of LDL-C in secondary prevention and poor intensification of statin therapy in the outpatient setting [24] .
Perspectives
Assessing therapy modifications to poorly controlled targets has been shown to be an additional measure of quality performance [13] . The 2013 AHA/ACC guidelines imply to treat all patients with ACS with an intensive statin regimen rather than targeting a specific goal of LDL-C [12] . Regarding the elderly (>75 years), moderate-intensity statin treatment is at minima recommended, as the benefit of high-intensity was not shown in this specific condition. However, the question of the best approach in terms of prevention of cardiovascular events remains open in this high risk group of patients with ACS. The point that adherence to guidelines that more easy to follow needs further explorations.
Limitations
The use of statin therapies was self-reported and not validated with a direct measure (e.g. pharmacy data), as such data are not available in Switzerland. We asked patients to bring the list of medications, as well as the pill boxes to confirm their statement and collected data on self-reported adherence by a validated questionnaire. Self-reported measure of medication adherence has been used in several publications and has been associated with clinical outcomes [22,25e28] . However, the achievement rate of LDL-C targets was similar after excluding those who did not report complete adherence. To check a potential selection bias due to missing LDL-C, we performed sensitivity analyses for statin prescription in those patients with missing LDL-C and found similar results, suggesting that participants with missing LDL-C were similarly treated. Furthermore, the ORs of associated factors were similar after adjusting for IPCW, suggesting that selection bias due to non-random drop-out was unlikely.
The SPUM-ACS cohort might not represent all patients with ACS, as only patients who gave consent were included. The recruitment period of the cohort preceded the publication of the 2013 AHA/ACC guidelines; for this reason, the findings of our study cannot be used Abbreviations: LDL-C, low-density lipoprotein cholesterol. Intensification of statin therapy was defined as a switch of a statin from a lower to a higher potency statin among patients discharged without high-intensity statin (no, low or moderate intensity statin).
for assessing physicians' behavior about the new guidelines. Finally, by nature of the inclusion criteria ACS, the baseline lipid levels were measured within the first 24 h of admission, but not necessarily in the fasting state. However, to take into account the potential modifications of lipid baseline profile after the onset of ACS symptoms, we excluded participants with chest pain duration greater than 24 h at admission, as their baseline lipid values may be lower than the stable values before the occurrence the ACS event. Intensification is defined by a switch to a higher potency statin if statin prescription was not high-intensity. The chi-square test was significant (P value < 0.001). Abbreviations: LDL-C, low-density lipoprotein cholesterol. For the assessment of targets at 1 year, the lipid panels have always been performed in a stable condition.
Conclusions
In patients with ACS, we found that applying criteria of the new 2013 AHA/ACC guidelines increased the proportion of patients on target compared to the previous 2004 ATP-III guidelines criteria. Our observations suggest that new 2013 AHA/ACC guidelines may be easier to follow for clinicians, but the impact of this change of paradigm on clinical cardiovascular outcomes needs to be described in further studies.
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